Antoni Ribas

About

Antoni Ribas, M.D., Ph.D., is a physician-scientist conducting laboratory and clinical research in malignant melanoma. His work focuses on gene engineered T-cells, PD-1 blockade therapy, and BRAF targeted therapies. His laboratory, supported by the National Cancer Institute, the State of California, and foundations, develops models of disease to test new therapeutic options, studies mechanisms of action of treatments in patients, and investigates the molecular mechanisms of therapy resistance. He has played a key role in the clinical development of several agents approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), cobimetinib (Cotellic), dabrafenib (Tafinlar), and trametinib (Mekinist).

Research topics

• Medicine
• Internal medicine
• Biology
• Immunology
• Cancer research
• Oncology
• Surgery
• Gastroenterology
• Virology
• Cell biology

Selected publications

• Multiple early factors anticipate post-acute COVID-19 sequelae

  Cell · 2022 · 1169 citations

  T cells exhibited unique dynamics during recovery from COVID-19. Analysis of symptom-associated immunological signatures revealed coordinated immunity polarization into four endotypes, exhibiting divergent acute severity and PASC. We find that immunological associations between PASC factors diminish over time, leading to distinct convalescent immune states. Detectability of most PASC factors at COVID-19 diagnosis emphasizes the importance of early disease measurements for understanding emergent…

  DOI

• Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

  New England Journal of Medicine · 2023-03-01 · 815 citations

  articleOpen accessSenior author

  BACKGROUND: Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage III or IV melanoma is unknown. METHODS: In a phase 2 trial, we randomly assigned patients with clinically detectable, measurable stage IIIB to IVC melanoma that was amenable to surgical resection to three doses of neoadjuvant pembrolizumab, sur…

  PublisherOA PDFDOI

• Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

  Cell · 2020 · 524 citations

  DOI

• Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

  Journal of Clinical Oncology · 2022 · 267 citations

  PURPOSE: The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study. We report the efficacy and safety from a phase III, randomized, double-blind, multicenter, international study of T-VEC plus pembrolizumab (T-VEC-pembrolizumab) versus placebo plus pembrolizumab (placebo-pembrolizumab) in patients with advanced melanoma. METHODS:…

  DOI

• Non-viral precision T cell receptor replacement for personalized cell therapy

  Nature · 2022 · 266 citations

  . Here we developed a clinical-grade approach based on CRISPR-Cas9 non-viral precision genome-editing to simultaneously knockout the two endogenous TCR genes TRAC (which encodes TCRα) and TRBC (which encodes TCRβ). We also inserted into the TRAC locus two chains of a neoantigen-specific TCR (neoTCR) isolated from circulating T cells of patients. The neoTCRs were isolated using a personalized library of soluble predicted neoantigen-HLA capture reagents. Sixteen patients with different refractory…

  DOI

Recent grants

• NIH Grant U54CA199090

  NIH · $22.6M · 2021

• NIH Grant T32CA009297

  NIH · $5.2M · 2014

• NIH Grant P01CA168585

  NIH · $16.9M · 2019

Frequent coauthors

• Georgina V. Long

  University of Sydney

  635 shared

• Bartosz Chmielowski

  425 shared

• Grant A. McArthur

  Victorian Comprehensive Cancer Centre

  414 shared

• Jeffrey A. Sosman

  Northwestern University

  411 shared

• Roger S. Lo

  411 shared

• Richard Kefford

  386 shared

• Begoña Comı́n-Anduix

  Parker Institute for Cancer Immunotherapy

  378 shared

• James S. Economou

  University of California, Los Angeles

  339 shared

Labs

• Antoni Ribas LaboratoryPI

Awards & honors

• President 2020, American Association for Cancer Research – A…

Similar researchers at University of California, Los Angeles

• Owen Witteh-170
• Edythe D. Londonh-115
• Thomas Graeberh-112